晚发型Stargardt 1型疾病研究:特征、遗传学与进展
这项回顾性队列研究纳入71例晚发型Stargardt 1型(STGD1)患者,中位发病年龄55.0岁,最常见基因型为ABCA4一个轻变异与一个重变异组合(69.0%),最常见等位基因为c.5603A→T(60.6%)。从发病到黄斑中心凹受累的中位时间为15.4年,中位视力下降为每年-0.03 Snellen小数视力,中位萎缩增长为每年0.590 mm²(明确减弱的自发荧光)和每年0.650 mm²(总减弱自发荧光)。作者认为应避免误诊为年龄相关性黄斑变性。
要点
- 晚发型STGD1中位发病年龄55.0岁,最常见为ABCA4一个轻变异与一个重变异组合(69.0%)。
- 从发病到黄斑中心凹受累的中位时间为15.4年(95%CI 11.1-19.6年)。
- 中位视力下降为每年-0.03 Snellen小数视力,中位萎缩增长为每年0.590-0.650 mm²。
核心结论
- 晚发型STGD1是STGD1的一种亚型,最常见为一个重变异与一个轻ABCA4变异组合。
- 患者通常表现为典型眼底黄色斑点和不累及黄斑中心凹的视网膜萎缩模式,中心视力保留。
- 应避免误诊为年龄相关性黄斑变性,以防无效的侵入性治疗及潜在并发症。
- 正确诊断使晚发型STGD1患者有机会参与可能获益的STGD1治疗试验。
研究设计与样本
- 回顾性队列研究,纳入71例晚发型STGD1患者,发病年龄定义为45岁或以上。
- 回顾病历收集临床数据,包括发病年龄、初始症状和最佳矫正视力。
- 在眼底自发荧光图像和OCT扫描上对RPE萎缩进行定量和定性评估。
- 主要结局指标为发病年龄、基因型、视力、萎缩增长速率以及外界膜、椭圆体带和RPE的丢失。
主要发现
- 中位发病年龄为55.0岁(范围45-82岁)。
- ABCA4一个轻变异与一个重变异组合是最常见基因型(n=49,69.0%)。
- 最常见等位基因c.5603A→T(p.Asn1868Ile)见于71例中的43例(60.6%)。
- 未发现两个重变异的组合。
- 首次就诊时所有患者均有黄色斑点;黄斑中心凹豁免萎缩占33.3%的眼,黄斑中心凹受累萎缩占21.1%的眼,中心凹外萎缩占38.9%的眼,6.7%的眼无明显萎缩。
关键数值与推荐
- 从发病到黄斑中心凹受累的中位时间为15.4年(95%CI 11.1-19.6年)。
- 中位视力下降为每年-0.03 Snellen小数视力(IQR -0.07至0.00 Snellen小数视力;0.03 logMAR)。
- 明确减弱的自发荧光中位萎缩增长为每年0.590 mm²(IQR 0.046-1.641 mm²/年)。
- 总减弱自发荧光中位萎缩增长为每年0.650 mm²(IQR 0.299-1.729 mm²/年)。
临床怎么用
- 作者认为应避免将晚发型STGD1误诊为年龄相关性黄斑变性,以防无效的侵入性治疗及潜在并发症。
- 作者指出正确诊断使晚发型STGD1患者有机会参与可能获益的STGD1治疗试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Late-onset Stargardt disease is a subtype of Stargardt disease type 1 (STGD1), defined by an age of onset of 45 years or older. We describe the disease characteristics, underlying genetics, and disease progression of late-onset STGD1 and highlight the differences from geographic atrophy. DESIGN: Retrospective cohort study. PARTICIPANTS: Seventy-one patients with late-onset STGD1. METHODS: Medical files were reviewed for clinical data including age at onset, initial symptoms, and best-corrected visual acuity. A quantitative and qualitative assessment of retinal pigment epithelium (RPE) atrophy was performed on fundus autofluorescence images and OCT scans. MAIN OUTCOME MEASURES: Age at onset, genotype, visual acuity, atrophy growth rates, and loss of external limiting membrane, ellipsoid zone, and RPE. RESULTS: Median age at onset was 55.0 years (range, 45-82 years). A combination of a mild and severe variant in ATP-binding cassette subfamily A member 4 (ABCA4) was the most common genotype (n = 49 [69.0%]). The most frequent allele, c.5603A→T (p.Asn1868Ile), was present in 43 of 71 patients (60.6%). No combination of 2 severe variants was found. At first presentation, all patients have flecks. Foveal-sparing atrophy was present in 33.3% of eyes, whereas 21.1% had atrophy with foveal involvement. Extrafoveal atrophy was present in 38.9% of eyes, and no atrophy was evident in 6.7% of eyes. Time-to-event curves showed a median duration of 15.4 years (95% confidence interval, 11.1-19.6 years) from onset to foveal involvement. The median visual acuity decline was -0.03 Snellen decimal per year (interquartile range [IQR], -0.07 to 0.00 Snellen decimal; 0.03 logarithm of the minimum angle of resolution). Median atrophy growth was 0.590 mm2/year (IQR, 0.046-1.641 mm2/year) for definitely decreased autofluorescence and 0.650 mm2/year (IQR, 0.299-1.729 mm2/year) for total decreased autofluorescence. CONCLUSIONS: Late-onset STGD1 is a subtype of STGD1 with most commonly 1 severe and 1 mild ABCA4 variant. The general patient presents with typical fundus flecks and retinal atrophy in a foveal-sparing pattern with preserved central vision. Misdiagnosis as age-related macular degeneration should be avoided to prevent futile invasive treatments with potential complications. In addition, correct diagnosis lends patients with late-onset STGD1 the opportunity to participate in potentially beneficial therapeutic trials for STGD1. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Li CHZ, Pas JAAH, Corradi Z, et al. Study of Late-Onset Stargardt Type 1 Disease: Characteristics, Genetics, and Progression. Ophthalmology. 2023. PMID: 37598860. doi:10.1016/j.ophtha.2023.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。